aca tirzepatide FDA says shortage is over after taking a second look Tirzepatide (Mounjaro) for the Treatment

The primary risks include gastrointestinal side effects (nausea, diarrhoea, vomiting) that may mask Crohn's flares, delayed gastric emptying potentially worsening strictures, dehydration leading to acute kidney injury, and appetite suppression that could worsen malnutrition in already underweight patients

Whilst off-label prescribing occurs, the licensed indication in the UK is for type 2 diabetes, and alternative approaches or the specifically licensed weight management formulation (Wegovy) may be more appropriate

Users reported symptoms affecting menstrual cycles and body temperature, which have not yet been described in clinical trials or included in drug labels

Reliance on pharmacotherapy alone risks delayed recognition of cirrhosis until complications develop

PMID 10880854